Cargando…

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy

BACKGROUND: Infliximab trough level (ITL) severely affects therapeutic outcomes of Crohn’s disease (CD) patients under infliximab (IFX). Recently, frontier research has focused on identifying ITL based on different therapeutic targets. Although previous studies have elaborated clinical value of ITL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Wan-Ting, Huang, Rong, Liu, Shan, Fan, Yi-Hong, Xu, Mao-Sheng, Xu, Yi, Ni, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254140/ https://www.ncbi.nlm.nih.gov/pubmed/35949356 http://dx.doi.org/10.3748/wjg.v28.i23.2582

Ejemplares similares

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
por: Park, Jihye, et al.
Publicado: (2023)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2020)

Body composition parameters correlate with the endoscopic severity in Crohn’s disease patients treated with infliximab
por: Tang, Wuli, et al.
Publicado: (2023)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn’s Disease on Infliximab Therapy
por: Almuntashri, Fahad, et al.
Publicado: (2021)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
por: Li, Shuyan, et al.
Publicado: (2023)

Correlation between Treatment Outcomes and Serum Vitamin D Levels As Well As Infliximab Trough Concentration among Chinese Patients with Crohn's Disease
por: Song, Xiaomei, et al.
Publicado: (2023)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Association of polymorphisms in C1orf106, IL1RN, and IL10 with post-induction infliximab trough level in Crohn’s disease patients
por: Tang, Jian, et al.
Publicado: (2019)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i649q1rbj11u7t1cgdquqcll42